Visual ImpairmentNCT06518148
Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification
An observational study of Visual Impairment, run by New Valley University at 1 site in Egypt.
Trial summary
Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification in Upper Egypt: A Retrospective Study Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Visual Impairment
- What is being tested?
- 1- uncorrected and best corrected visual acuity (UCVA and BCVA) by Snellen's-chart.2-slit lamp bio microscopy (Haag-Streit, USA).3-IOP measurements (Goldmann Applanation tonometer)
- How many people
- 2,000 participants
- Where
- 1 siteEgypt
- Study dates
- 20 Apr 2024to 20 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients referred to The Ministry of Social Solidarity with visual Disability in upper Egypt who were examined in the visual disability screening program from 2020-2024-no age or gender limits for the study.
Who may be able to join
- All patients referred to The Ministry of Social Solidarity with visual Disability in upper Egypt who were examined in the visual disability screening program from 2020-2024.
Who cannot join
- The patients who had decreased vision but did not fit with the WHO definition of visual disability.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification in Upper Egypt: A Retrospective Study
Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification in Upper Egypt: A Retrospective Study
Read the detailed description
There are at least 2.2 billion individuals with near- or far-sightedness worldwide. Nearly half of these cases-at At least 1 billion-have untreated vision impairment that may have been avoided. The leading cause of blindness or impaired distant vision among these 1 billion people is diabetic retinopathy (3.9 million), age-related macular degeneration (8 million), cataracts (94 million), refractive error (88.4 million), and glaucoma (7.7 million). Presbyopia (826 million) is the primary ailment that impairs close vision.
According to estimates, there are four times as many cases of distant vision impairment in low- and middle-income areas as there are in high-income areas.
Aging populations and population expansion are predicted to raise the likelihood that more people may have visual impairment. Early on, irreversible severe visual impairment in young children can lead to delayed motor, verbal, emotional, social, and cognitive development, which can have long-term effects. Children of school age who are visually impaired may also perform less academically. The quality of life is significantly impacted by vision impairment in adult populations. Adults who are visually impaired may have greater rates of anxiety and depression as well as decreased employment rates.
Vision impairment in older persons can increase their risk of falling and breaking bones, walking difficulties, social isolation, and early admission into nursing homes or other care facilities.
According to estimates, vision impairment costs the world's economy $411 billion annually in lost productivity (purchasing power parity) . This amount is greatly above the predicted $25 billion cost gap incurred from treating vision impairment.
This study is to demonstrate the causes of visual impairment in upper Egypt among the different age groups and evaluate the possibility of preventing these disorders
- Conditions
- Visual Impairment
- Being tested
- 1- uncorrected and best corrected visual acuity (UCVA and BCVA) by Snellen's-chart.2-slit lamp bio microscopy (Haag-Streit, USA).3-IOP measurements (Goldmann Applanation tonometer)
- Medical subject headings
- Vision Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
1- uncorrected and best corrected visual acuity (UCVA and BCVA) by Snellen's-chart.2-slit lamp bio microscopy (Haag-Streit, USA).3-IOP measurements (Goldmann Applanation tonometer)Diagnostic test
Also called 3-fundus examination (+90D lens and indirect ophthalmoscope)., 4- Electrophysiological study visual evoked potential (VEP) and full filed electroretinogram (Metrovision machine).
diagnostic test;UCVA, IOP, Electrophysiological study
What is being measured
The primary outcome is the main question the study is designed to answer.
The relative frequencies or prevalence of different eye diseases/conditions causing visual disability
Measured: 10 month
2-Ranking of the leading cause(s) of visual impairment
Measured: 10 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2024
- Study start20 Apr 2024
- Primary completion20 Dec 2025 (estimated)
- Study completion20 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Visual ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 2,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- New Valley University
- Sponsor type
- University, hospital or other
- Collaborators
- Assiut University
- Responsible party
- Principal investigator, Asmaa Kamel Ahmed Hassan, New Valley University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06518148
- Sponsor's protocol ID
- CVIAPAVDCUE
- Status last verified
- Aug 2025
- First submitted
- 14 Jul 2024
- Last updated
- 4 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: we share in a multicenter study.
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification in Upper Egypt: A Retrospective Study
- ClinicalTrials.gov ID
- NCT06518148
- Acronym / sponsor ID
- CVIAPAVDCUE
- Conditions
- Visual Impairment
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 2,000 participants (actual)
- Lead sponsor
- New Valley UniversityUniversity, hospital or other
- Collaborators
- Assiut University
- Study start
- 20 Apr 2024 (actual)
- Primary completion
- 20 Dec 2025 (estimated)
- Study completion
- 20 Dec 2025 (estimated)
- First posted
- 24 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification in Upper Egypt: A Retrospective Study
Detailed description
There are at least 2.2 billion individuals with near- or far-sightedness worldwide. Nearly half of these cases-at At least 1 billion-have untreated vision impairment that may have been avoided. The leading cause of blindness or impaired distant vision among these 1 billion people is diabetic retinopathy (3.9 million), age-related macular degeneration (8 million), cataracts (94 million), refractive error (88.4 million), and glaucoma (7.7 million). Presbyopia (826 million) is the primary ailment that impairs close vision.
According to estimates, there are four times as many cases of distant vision impairment in low- and middle-income areas as there are in high-income areas.
Aging populations and population expansion are predicted to raise the likelihood that more people may have visual impairment. Early on, irreversible severe visual impairment in young children can lead to delayed motor, verbal, emotional, social, and cognitive development, which can have long-term effects. Children of school age who are visually impaired may also perform less academically. The quality of life is significantly impacted by vision impairment in adult populations. Adults who are visually impaired may have greater rates of anxiety and depression as well as decreased employment rates.
Vision impairment in older persons can increase their risk of falling and breaking bones, walking difficulties, social isolation, and early admission into nursing homes or other care facilities.
According to estimates, vision impairment costs the world's economy $411 billion annually in lost productivity (purchasing power parity) . This amount is greatly above the predicted $25 billion cost gap incurred from treating vision impairment.
This study is to demonstrate the causes of visual impairment in upper Egypt among the different age groups and evaluate the possibility of preventing these disorders
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients referred to The Ministry of Social Solidarity with visual Disability in upper Egypt who were examined in the visual disability screening program from 2020-2024-no age or gender limits for the study.
Key inclusion criteria (1 listed)
- All patients referred to The Ministry of Social Solidarity with visual Disability in upper Egypt who were examined in the visual disability screening program from 2020-2024.
Key exclusion criteria (1 listed)
- The patients who had decreased vision but did not fit with the WHO definition of visual disability.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 1- uncorrected and best corrected visual acuity (UCVA and BCVA) by Snellen's-chart.2-slit lamp bio microscopy (Haag-Streit, USA).3-IOP measurements (Goldmann Applanation tonometer)Also: 3-fundus examination (+90D lens and indirect ophthalmoscope)., 4- Electrophysiological study visual evoked potential (VEP) and full filed electroretinogram (Metrovision machine).diagnostic test;UCVA, IOP, Electrophysiological study | Diagnostic test | – |
Primary outcome
The relative frequencies or prevalence of different eye diseases/conditions causing visual disability
Time frame: 10 month
2-Ranking of the leading cause(s) of visual impairment
Time frame: 10 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2025.
- Individual participant dataSharing planned: Undecided. we share in a multicenter study.
Related trials for Visual Impairment
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Not yet recruiting
NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia
Schizophrenia, Schizoaffective Disorder
Not yet recruiting
Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss
Macular Degeneration, Central Visual Impairment
Not yet recruiting
joyVision: The Superiority of Co-design in the Development of a Serious Game for Children With Cerebral Visual Impairment
Cerebral Visual Impairment
RecruitingPhase 3
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Radiation Retinopathy, Visual Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Visual Impairment, run by New Valley University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The relative frequencies or prevalence of different eye diseases/conditions causing visual disability (time frame: 10 month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2025; AzTrials last refreshed its copy on 7 Nov 2026.